paroxetine has been researched along with perphenazine in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Begley, A; Cornes, C; Dew, MA; Frank, E; Hall, M; Houck, PR; Kupfer, DJ; Mazumdar, S; Miller, MD; Mulsant, B; Perel, JM; Reynolds, CF; Shear, MK | 1 |
| Young, C | 1 |
| Herrmann, N; Kalow, W; Naranjo, CA; Ozdemir, V; Reed, K; Sellers, EM | 1 |
| Preskorn, SH; Shad, MU | 1 |
| Bartel, RL; Goodhue, A; Smith, NB | 1 |
| Preskorn, SH | 1 |
1 review(s) available for paroxetine and perphenazine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for paroxetine and perphenazine
| Article | Year |
|---|---|
High relapse rate after discontinuation of adjunctive medication for elderly patients with recurrent major depression.
Topics: Age Factors; Age of Onset; Aged; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder; Double-Blind Method; Drug Therapy, Combination; Female; Hospitalization; Humans; Lithium; Male; Nortriptyline; Paroxetine; Perphenazine; Placebos; Psychotherapy; Recurrence; Risk Factors; Treatment Outcome | 1996 |
Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.
Topics: Adult; Analysis of Variance; Central Nervous System; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dopamine Antagonists; Double-Blind Method; Drug Synergism; Humans; Memory; Middle Aged; Paroxetine; Perphenazine; Psychomotor Performance; Selective Serotonin Reuptake Inhibitors | 1997 |
12 other study(ies) available for paroxetine and perphenazine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
A case of neuroleptic malignant syndrome and serotonin disturbance.
Topics: Akathisia, Drug-Induced; Benztropine; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lithium Carbonate; Middle Aged; Neuroleptic Malignant Syndrome; Neurologic Examination; Paroxetine; Perphenazine; Receptors, Serotonin; Trazodone | 1997 |
Pharmacodynamic and pharmacokinetic factors in a case of neuroleptic malignant syndrome.
Topics: Antipsychotic Agents; Brain; Drug Interactions; Drug Therapy, Combination; Humans; Lithium Carbonate; Neuroleptic Malignant Syndrome; Paroxetine; Perphenazine; Selective Serotonin Reuptake Inhibitors; Trazodone | 1998 |
Exacerbation of psychosis by phenylpropanolamine.
Topics: Adult; Female; Hallucinations; Humans; Methamphetamine; Nasal Decongestants; Paranoid Disorders; Paroxetine; Perphenazine; Phenylpropanolamine; Psychoses, Substance-Induced; Recurrence; Substance-Related Disorders | 2000 |
Neuroleptic malignant syndrome resulting from a complex drug-drug interaction: "I don't see 'em!".
Topics: Benztropine; Bipolar Disorder; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Humans; Lithium Compounds; Middle Aged; Neuroleptic Malignant Syndrome; Paroxetine; Perphenazine; Psychotropic Drugs; Trazodone | 2007 |